

Fibroblast Growth Factor 21 Prevents Atherosclerosis by Regulatory Element-Binding Protein-2 and Induction of

Circulation

131, 1861-1871

DOI: [10.1161/circulationaha.115.015308](https://doi.org/10.1161/circulationaha.115.015308)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2015, 14, 72.	2.7	62
2	Fibroblast growth factor 21 deletion aggravates diabetes-induced pathogenic changes in the aorta in type 1 diabetic mice. <i>Cardiovascular Diabetology</i> , 2015, 14, 77.	2.7	19
3	Vascular protection with fibroblast growth factor 21 in diabetes: Its potential beyond glucose and lipid control. <i>International Journal of Cardiology</i> , 2015, 199, 403-404.	0.8	2
4	Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2015, 309, H1029-H1038.	1.5	78
5	Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases. <i>Molecular Endocrinology</i> , 2015, 29, 1400-1413.	3.7	106
6	Dietary Niacin Supplementation Suppressed Hepatic Lipid Accumulation in Rabbits. <i>Asian-Australasian Journal of Animal Sciences</i> , 2016, 29, 1748-1755.	2.4	15
7	Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-8.	1.0	37
8	Fibroblast Growth Factor 21 Protects against Atherosclerosis via Fine-Tuning the Multiorgan Crosstalk. <i>Diabetes and Metabolism Journal</i> , 2016, 40, 22.	1.8	42
9	Metformin promotes cholesterol efflux in macrophages by up-regulating FGF21 expression: a novel anti-atherosclerotic mechanism. <i>Lipids in Health and Disease</i> , 2016, 15, 109.	1.2	19
10	FGF21 represses cerebrovascular aging via improving mitochondrial biogenesis and inhibiting p53 signaling pathway in an AMPK-dependent manner. <i>Experimental Cell Research</i> , 2016, 346, 147-156.	1.2	43
11	FGF21 ameliorates the neurocontrol of blood pressure in the high fructose-drinking rats. <i>Scientific Reports</i> , 2016, 6, 29582.	1.6	30
12	Single ingestion of soy β -conglycinin induces increased postprandial circulating FGF21 levels exerting beneficial health effects. <i>Scientific Reports</i> , 2016, 6, 28183.	1.6	42
13	Shedding light on FGF21: A potential negative regulator of PCSK9. <i>International Journal of Cardiology</i> , 2016, 214, 75-76.	0.8	8
14	Targeting endoplasmic reticulum stress in liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1041-1052.	1.4	34
15	Comprehensive Metabolomic Characterization of Coronary Artery Diseases. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1281-1293.	1.2	186
16	Association Between Serum Fibroblast Growth Factor 21 and Mortality Among Patients With Coronary Artery Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4886-4894.	1.8	41
17	A Fibroblast Growth Factor 21 α -Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease. <i>Molecular Pharmacology</i> , 2016, 90, 437-446.	1.0	22
18	The progress and challenges in metabolic research in China. <i>IUBMB Life</i> , 2016, 68, 847-853.	1.5	7

#	ARTICLE	IF	CITATIONS
19	Hyperlipidemia and hepatitis in liver-specific CREB3L3 knockout mice generated using a one-step CRISPR/Cas9 system. <i>Scientific Reports</i> , 2016, 6, 27857.	1.6	31
20	Fibroblast growth factor 21 potentially inhibits microRNA-33 expression to affect macrophage actions. <i>Lipids in Health and Disease</i> , 2016, 15, 208.	1.2	9
21	Serum concentrations of fibroblast growth factor 21 are elevated in patients with congenital or acquired lipodystrophy. <i>Cytokine</i> , 2016, 83, 239-244.	1.4	18
22	Common links between metabolic syndrome and inflammatory bowel disease: Current overview and future perspectives. <i>Pharmacological Reports</i> , 2016, 68, 837-846.	1.5	43
23	The FGF21-â€œadiponectin axis in controlling energy and vascular homeostasis. <i>Journal of Molecular Cell Biology</i> , 2016, 8, 110-119.	1.5	68
24	Overexpression of β -Klotho in Adipose Tissue Sensitizes Male Mice to Endogenous FGF21 and Provides Protection From Diet-Induced Obesity. <i>Endocrinology</i> , 2016, 157, 1467-1480.	1.4	55
25	Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 393-403.	1.4	25
26	Practical prospects for boosting hepatic production of the â€œpro-longevityâ€•hormone FGF21. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2017, 30, .	0.3	4
27	The moderate essential amino acid restriction entailed by low-protein vegan diets may promote vascular health by stimulating FGF21 secretion. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2017, 30, .	0.3	10
28	Fibroblast growth factor 21 â€œ a key player in cardiovascular disorders?. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2017, 30, .	0.3	4
29	Mouse models of atherosclerosis: a historical perspective and recent advances. <i>Lipids in Health and Disease</i> , 2017, 16, 12.	1.2	130
30	Role of Circulating Fibroblast Growth Factor 21 Measurement in Primary Prevention of Coronary Heart Disease Among Chinese Patients With Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	29
31	Haematopoietic TLR4 deletion attenuates perivascular brown adipose tissue inflammation in atherosclerotic mice. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2017, 1862, 946-957.	1.2	12
32	FGF21 ameliorates diabetic cardiomyopathy by activating the AMPK-paraoxonase 1 signaling axis in mice. <i>Clinical Science</i> , 2017, 131, 1877-1893.	1.8	38
33	The Potential Role of Fibroblast Growth Factor 21 in Lipid Metabolism and Hypertension. <i>Current Hypertension Reports</i> , 2017, 19, 28.	1.5	52
34	The role of fibroblast growth factor 21 in atherosclerosis. <i>Atherosclerosis</i> , 2017, 257, 259-265.	0.4	54
35	Fibroblast growth factor 21 attenuates calcification of vascular smooth muscle cells in vitro. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 69, 1802-1816.	1.2	26
36	Integrated stress response stimulates FGF21 expression: Systemic enhancer of longevity. <i>Cellular Signalling</i> , 2017, 40, 10-21.	1.7	72

#	ARTICLE	IF	CITATIONS
37	The FGF21-CCL11 Axis Mediates Beiging of White Adipose Tissues by Coupling Sympathetic Nervous System to Type 2 Immunity. <i>Cell Metabolism</i> , 2017, 26, 493-508.e4.	7.2	113
38	Rush to the fire: FGF21 extinguishes metabolic stress, metaflammation and tissue damage. <i>Cytokine and Growth Factor Reviews</i> , 2017, 38, 59-65.	3.2	41
39	Associations of fibroblast growth factor 21 with cardiovascular risk and β^2 -cell function in patients who had no history of diabetes. <i>Clinica Chimica Acta</i> , 2017, 472, 80-85.	0.5	5
40	Fibroblast Growth Factor 21â€™Metabolic Role in Mice and Men. <i>Endocrine Reviews</i> , 2017, 38, 468-488.	8.9	192
41	Fibroblast growth factor 21 plays an inhibitory role in vascular calcification inÂvitro through OPG/RANKL system. <i>Biochemical and Biophysical Research Communications</i> , 2017, 491, 578-586.	1.0	19
42	Combination treatment of adipose-derived stem cells and adiponectin attenuates pulmonary arterial hypertension in rats by inhibiting pulmonary arterial smooth muscle cell proliferation and regulating the AMPK/BMP/Smad pathway. <i>International Journal of Molecular Medicine</i> , 2017, 41, 51-60.	1.8	26
43	Citreoviridin induces triglyceride accumulation in hepatocytes through inhibiting PPAR- β inÂvivo and inÂvitro. <i>Chemico-Biological Interactions</i> , 2017, 273, 212-218.	1.7	6
44	FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPAR β and PPAR δ Agonists. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 834-845.	3.1	44
45	Sarcopenic obesity or obese sarcopenia: A cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis. <i>Ageing Research Reviews</i> , 2017, 35, 200-221.	5.0	483
46	Fibroblast Growth Factor 21 Mimetics for Treating Atherosclerosis. <i>Endocrinology and Metabolism</i> , 2017, 32, 145.	1.3	8
47	Adrenergic receptor-mediated activation of FGF-21-adiponectin axis exerts atheroprotective effects in brown adipose tissue-transplanted apoE mice. <i>Biochemical and Biophysical Research Communications</i> , 2018, 497, 1097-1103.	1.0	11
48	FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2/Angiotensin-(1â€™7) Axis in Mice. <i>Cell Metabolism</i> , 2018, 27, 1323-1337.e5.	7.2	104
49	Dietary protein dilution limits dyslipidemia in obesity through FGF21-driven fatty acid clearance. <i>Journal of Nutritional Biochemistry</i> , 2018, 57, 189-196.	1.9	31
50	Fibroblast growth factor-21 prevents diabetic cardiomyopathy via AMPK-mediated antioxidation and lipid-lowering effects in the heart. <i>Cell Death and Disease</i> , 2018, 9, 227.	2.7	85
51	Fibroblast growth factor 21 in cardio-metabolic disorders: a systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2018, 83, 11-17.	1.5	51
52	Pharmacokinetics, tissue distribution, and excretion of FGFâ€™21 following subcutaneous administration in rats. <i>Drug Testing and Analysis</i> , 2018, 10, 1061-1069.	1.6	5
53	The relationship of circulating fibroblast growth factor 21 levels with incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis. <i>Atherosclerosis</i> , 2018, 269, 86-91.	0.4	9
54	Conditioned medium from contracting skeletal muscle cells reverses insulin resistance and dysfunction of endothelial cells. <i>Metabolism: Clinical and Experimental</i> , 2018, 82, 36-46.	1.5	14

#	ARTICLE	IF	CITATIONS
56	FGF21 induced by carbon monoxide mediates metabolic homeostasis via the PERK/ATF4 pathway. <i>FASEB Journal</i> , 2018, 32, 2630-2643.	0.2	39
57	The role of suppression of hepatic SCD1 expression in the metabolic effects of dietary methionine restriction. <i>Applied Physiology, Nutrition and Metabolism</i> , 2018, 43, 123-130.	0.9	6
58	Fibroblast growth factors 19 and 21 in acute liver damage. <i>Annals of Translational Medicine</i> , 2018, 6, 257-257.	0.7	11
59	Acid fibroblast growth factor facilitates the progression of atherosclerotic plaques regardless of alterations in serum lipid expression levels in HFD-fed ApoE ^{-/-} mice. <i>Molecular Medicine Reports</i> , 2018, 18, 1025-1030.	1.1	3
60	Cholesterol Efflux: Does It Contribute to Aortic Stiffening?. <i>Journal of Cardiovascular Development and Disease</i> , 2018, 5, 23.	0.8	8
61	Endocrine Regulator rFGF21 (Recombinant Human Fibroblast Growth Factor 21) Improves Neurological Outcomes Following Focal Ischemic Stroke of Type 2 Diabetes Mellitus Male Mice. <i>Stroke</i> , 2018, 49, 3039-3049.	1.0	36
62	Adiposity Is a Key Correlate of Circulating Fibroblast Growth Factor-21 Levels in African Males with or without Type 2 Diabetes Mellitus. <i>Journal of Obesity</i> , 2018, 2018, 1-8.	1.1	9
63	Fibroblast growth factor 21 regulates foam cells formation and inflammatory response in Ox-LDL-induced THP-1 macrophages. <i>Biomedicine and Pharmacotherapy</i> , 2018, 108, 1825-1834.	2.5	35
64	Fibroblast growth factor 21 inhibits atherosclerosis in apoE ^{-/-} mice by ameliorating Fas-mediated apoptosis. <i>Lipids in Health and Disease</i> , 2018, 17, 203.	1.2	23
65	The role of FGF21 in type 1 diabetes and its complications. <i>International Journal of Biological Sciences</i> , 2018, 14, 1000-1011.	2.6	23
66	CREBH Regulates Systemic Glucose and Lipid Metabolism. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1396.	1.8	62
67	FGF Family: From Drug Development to Clinical Application. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1875.	1.8	110
68	A2A Receptor Activation Attenuates Hypertensive Cardiac Remodeling via Promoting Brown Adipose Tissue-Derived FGF21. <i>Cell Metabolism</i> , 2018, 28, 476-489.e5.	7.2	80
69	RPS3A positively regulates the mitochondrial function of human periaortic adipose tissue and is associated with coronary artery diseases. <i>Cell Discovery</i> , 2018, 4, 52.	3.1	21
70	Low Plasma Levels of Fibroblast Growth Factor-21 in Patients with Peripheral Artery Disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 821-828.	0.9	10
71	Endothelial cell senescence in aging-related vascular dysfunction. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 1802-1809.	1.8	232
72	Association between Circulating Fibroblast Growth Factor 21 and Aggressiveness in Thyroid Cancer. <i>Cancers</i> , 2019, 11, 1154.	1.7	23
73	The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease. , 2019, 203, 107401.		86

#	ARTICLE	IF	CITATIONS
74	Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease. <i>Clinica Chimica Acta</i> , 2019, 498, 30-37.	0.5	28
75	Lyophilized Maqui (<i>Aristotelia chilensis</i>) Berry Induces Browning in the Subcutaneous White Adipose Tissue and Ameliorates the Insulin Resistance in High Fat Diet-Induced Obese Mice. <i>Antioxidants</i> , 2019, 8, 360.	2.2	28
76	Inhibition of vascular neointima hyperplasia by FGF21 associated with FGFR1/Syk/NLRP3 inflammasome pathway in diabetic mice. <i>Atherosclerosis</i> , 2019, 289, 132-142.	0.4	36
77	The FGF metabolic axis. <i>Frontiers of Medicine</i> , 2019, 13, 511-530.	1.5	97
78	Fibroblast growth factor 21 Ameliorates diabetes-induced endothelial dysfunction in mouse aorta via activation of the CaMKK2/AMPK β signaling pathway. <i>Cell Death and Disease</i> , 2019, 10, 665.	2.7	37
79	Effects of granulocyte colony-stimulating factor on rabbit carotid and porcine heart models of chronic obliterative arterial disease. <i>Molecular Medicine Reports</i> , 2019, 19, 4569-4578.	1.1	0
80	Therapeutic effect of dichloroacetate against atherosclerosis via hepatic FGF21 induction mediated by acute AMPK activation. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-12.	3.2	13
81	Adiponectin improves diabetic nephropathy by inhibiting necrotic apoptosis. <i>Archives of Medical Science</i> , 2019, 15, 1321-1328.	0.4	21
82	Fibroblast Growth Factor 21 Attenuates Vascular Calcification by Alleviating Endoplasmic Reticulum Stress Mediated Apoptosis in Rats. <i>International Journal of Biological Sciences</i> , 2019, 15, 138-147.	2.6	36
83	Mutual promotion of FGF21 and PPAR β attenuates hypoxia-induced pulmonary hypertension. <i>Experimental Biology and Medicine</i> , 2019, 244, 252-261.	1.1	18
84	Relationship of fibroblast growth factor 21 with subclinical atherosclerosis and cardiovascular events: Multi-Ethnic Study of Atherosclerosis. <i>Atherosclerosis</i> , 2019, 287, 46-53.	0.4	17
85	Fibroblast growth factor 21 ameliorates pancreatic fibrogenesis via regulating polarization of macrophages. <i>Experimental Cell Research</i> , 2019, 382, 111457.	1.2	22
86	A review of fibroblast growth factor 21 in diabetic cardiomyopathy. <i>Heart Failure Reviews</i> , 2019, 24, 1005-1017.	1.7	26
87	Monocyte chemoattractant protein-1 (MCP-1) and fibroblast growth factor-21 (FGF-21) as biomarkers of subclinical atherosclerosis in women. <i>Experimental Gerontology</i> , 2019, 124, 110624.	1.2	24
88	Growth Factors as Immunotherapeutic Targets in Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1275-1287.	1.1	36
89	Exercise Alleviates Obesity-Induced Metabolic Dysfunction via Enhancing FGF21 Sensitivity in Adipose Tissues. <i>Cell Reports</i> , 2019, 26, 2738-2752.e4.	2.9	115
90	FGF21 Protects Against Hypoxia Injury Through Inducing HSP72 in Cerebral Microvascular Endothelial Cells. <i>Frontiers in Pharmacology</i> , 2019, 10, 101.	1.6	22
91	Emerging role of proprotein convertase subtilisin/kexin type-9 (PCSK-9) in inflammation and diseases. <i>Toxicology and Applied Pharmacology</i> , 2019, 370, 170-177.	1.3	18

#	ARTICLE	IF	CITATIONS
92	The roles of FGF21 in atherosclerosis pathogenesis. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2019, 20, 103-114.	2.6	27
93	Emerging Structure-Function Paradigm of Endocrine FGFs in Metabolic Diseases. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 142-153.	4.0	24
94	Fibroblast growth factor 21 in chronic kidney disease. <i>Journal of Nephrology</i> , 2019, 32, 365-377.	0.9	38
95	Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signaling-dependent manner. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 1059-1071.	1.6	39
96	Fibroblast growth factor 21 association with subclinical atherosclerosis and arterial stiffness in type 2 diabetes. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 882-888.	1.8	16
97	Independent links between plasma xanthine oxidoreductase activity and levels of adipokines. <i>Journal of Diabetes Investigation</i> , 2019, 10, 1059-1067.	1.1	40
98	Fibroblast growth factor 21 in chronic kidney disease. <i>Clinica Chimica Acta</i> , 2019, 489, 196-202.	0.5	29
99	Therapeutic Role of Fibroblast Growth Factor 21 (FGF21) in the Amelioration of Chronic Diseases. <i>International Journal of Peptide Research and Therapeutics</i> , 2020, 26, 107-119.	0.9	8
100	Organokines in disease. <i>Advances in Clinical Chemistry</i> , 2020, 94, 261-321.	1.8	24
101	Adipokines and Inflammation: Focus on Cardiovascular Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7711.	1.8	48
103	Dysregulated lipid metabolism links NAFLD to cardiovascular disease. <i>Molecular Metabolism</i> , 2020, 42, 101092.	3.0	197
104	Emerging insights into the relationship between hyperlipidemia and the risk of diabetic retinopathy. <i>Lipids in Health and Disease</i> , 2020, 19, 241.	1.2	27
105	The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. <i>Nature Reviews Endocrinology</i> , 2020, 16, 654-667.	4.3	280
106	Structures and anti-atherosclerotic effects of 1,6- β -glucans from Fructus Corni. <i>International Journal of Biological Macromolecules</i> , 2020, 161, 1346-1357.	3.6	17
108	FGF21 alleviates neuroinflammation following ischemic stroke by modulating the temporal and spatial dynamics of microglia/macrophages. <i>Journal of Neuroinflammation</i> , 2020, 17, 257.	3.1	97
109	Effect of Fibroblast Growth Factor 21 on the Development of Atheromatous Plaque and Lipid Metabolic Profiles in an Atherosclerosis-Prone Mouse Model. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6836.	1.8	11
110	FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. <i>Frontiers in Endocrinology</i> , 2020, 11, 601290.	1.5	111
111	Fibroblast Growth Factor 21 is Related to Atherosclerosis Independent of Nonalcoholic Fatty Liver Disease and Predicts Atherosclerotic Cardiovascular Events. <i>Journal of the American Heart Association</i> , 2020, 9, e015226.	1.6	34

#	ARTICLE	IF	CITATIONS
112	Pulse Wave Velocity Is Associated with Increased Plasma oxLDL in Ageing but Not with FGF21 and Habitual Exercise. <i>Antioxidants</i> , 2020, 9, 221.	2.2	3
113	Effect of Berberine on Atherosclerosis and Gut Microbiota Modulation and Their Correlation in High-Fat Diet-Fed ApoE ^{-/-} /A ^{+/+} Mice. <i>Frontiers in Pharmacology</i> , 2020, 11, 223.	1.6	129
114	Effects of exercise training and detraining on atheromatous matrix metalloproteinase activity in mice. <i>Atherosclerosis</i> , 2020, 299, 15-23.	0.4	3
115	A novel selective PPAR α modulator, pemafibrate promotes ischemia-induced revascularization through the eNOS-dependent mechanisms. <i>PLoS ONE</i> , 2020, 15, e0235362.	1.1	12
116	Adenosine A2A receptor activation prevents DOCA-salt induced hypertensive cardiac remodeling via iBAT. <i>Biochemical and Biophysical Research Communications</i> , 2020, 525, 224-230.	1.0	5
117	Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases. <i>Circulation Research</i> , 2020, 126, 679-704.	2.0	121
118	Growth factor regulatory system: a new system for not truly recognized organisms. <i>Science China Life Sciences</i> , 2020, 63, 443-446.	2.3	2
119	Serum fibroblast growth factor 21 level is increased in pre-eclampsia patients: Association with blood pressure and lipid profile. <i>Journal of Obstetrics and Gynaecology Research</i> , 2021, 47, 375-381.	0.6	6
120	Enterohepatic Transcription Factor CREB3L3 Protects Atherosclerosis via SREBP Competitive Inhibition. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 949-971.	2.3	11
121	Epigenetic Regulation of Processes Related to High Level of Fibroblast Growth Factor 21 in Obese Subjects. <i>Genes</i> , 2021, 12, 307.	1.0	8
122	Mesenchymal stem cells modified by FGF21 and GLP1 ameliorate lipid metabolism while reducing blood glucose in type 2 diabetic mice. <i>Stem Cell Research and Therapy</i> , 2021, 12, 133.	2.4	14
123	Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse Model. <i>Endocrinology and Metabolism</i> , 2021, 36, 157-170.	1.3	11
124	Unlocking the Therapeutic Potential of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination for the Pathogenesis of Atherosclerosis in Type 2 Diabetes. <i>Endocrinology and Metabolism</i> , 2021, 36, 57-59.	1.3	1
125	FGF21 promotes ischaemic angiogenesis and endothelial progenitor cells function under diabetic conditions in an AMPK/NAD ⁺ -dependent manner. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 3091-3102.	1.6	21
126	Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis. <i>Cardiovascular Research</i> , 2022, 118, 489-502.	1.8	34
127	Association between serum fibroblast growth factor 21 level and sight-threatening diabetic retinopathy in Chinese patients with type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002126.	1.2	5
128	Roles of Fibroblast Growth Factors and Their Therapeutic Potential in Treatment of Ischemic Stroke. <i>Frontiers in Pharmacology</i> , 2021, 12, 671131.	1.6	29
129	Myeloid-derived growth factor inhibits inflammation and alleviates endothelial injury and atherosclerosis in mice. <i>Science Advances</i> , 2021, 7, .	4.7	33

#	ARTICLE	IF	CITATIONS
130	FGF21 and Chronic Kidney Disease. <i>Metabolism: Clinical and Experimental</i> , 2021, 118, 154738.	1.5	15
131	The potential role of plasma fibroblast growth factor 21 as a diagnostic biomarker for abdominal aortic aneurysm presence and development. <i>Life Sciences</i> , 2021, 274, 119346.	2.0	6
132	Beta-klotho in type 2 diabetes mellitus: From pathophysiology to therapeutic strategies. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 1091-1109.	2.6	14
133	Peptidoglycan Recognition Protein 1 Attenuates Atherosclerosis by Suppressing Endothelial Cell Adhesion. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 78, 615-621.	0.8	4
134	BMP4-mediated browning of perivascular adipose tissue governs an anti-inflammatory program and prevents atherosclerosis. <i>Redox Biology</i> , 2021, 43, 101979.	3.9	18
135	The Role of Fibroblast Growth Factor 21 in Diabetic Cardiovascular Complications and Related Epigenetic Mechanisms. <i>Frontiers in Endocrinology</i> , 2021, 12, 598008.	1.5	5
136	Elabela prevents angiotensin II-induced apoptosis and inflammation in rat aortic adventitial fibroblasts via the activation of FGF21-ACE2 signaling. <i>Journal of Molecular Histology</i> , 2021, 52, 905-918.	1.0	10
137	Estrogen-Wnt signaling cascade regulates expression of hepatic fibroblast growth factor 21. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 321, E292-E304.	1.8	11
138	High-Level Serum Fibroblast Growth Factor 21 Concentration Is Closely Associated With an Increased Risk of Cardiovascular Diseases: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 705273.	1.1	12
139	CREBH Systemically Regulates Lipid Metabolism by Modulating and Integrating Cellular Functions. <i>Nutrients</i> , 2021, 13, 3204.	1.7	2
140	FGF21 ameliorates hepatic fibrosis by multiple mechanisms. <i>Molecular Biology Reports</i> , 2021, 48, 7153-7163.	1.0	10
141	CREBH normalizes dyslipidemia and halts atherosclerosis in diabetes by decreasing circulating remnant lipoproteins. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	12
142	Fibroblast growth factor 21 in dairy cows: current knowledge and potential relevance. <i>Journal of Animal Science and Biotechnology</i> , 2021, 12, 97.	2.1	9
143	Association of Coronary Artery Disease and Metabolic Syndrome: Usefulness of Serum Metabolomics Approach. <i>Frontiers in Endocrinology</i> , 2021, 12, 692893.	1.5	8
144	Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1276, 137-156.	0.8	18
145	Neuropilin-2 promotes growth and progression of papillary thyroid cancer cells. <i>Auris Nasus Larynx</i> , 2020, 47, 870-880.	0.5	9
146	FGF21 mitigates atherosclerosis via inhibition of NLRP3 inflammasome-mediated vascular endothelial cells pyroptosis. <i>Experimental Cell Research</i> , 2020, 393, 112108.	1.2	59
147	Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis. <i>Clinical Science</i> , 2020, 134, 1775-1799.	1.8	25

#	ARTICLE	IF	CITATIONS
148	Current understanding and controversies on the clinical implications of fibroblast growth factor 21. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2021, 58, 311-328.	2.7	7
149	Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial. <i>PLoS ONE</i> , 2015, 10, e0133496.	1.1	84
150	Metabolic remodeling induced by mitokines in heart failure. <i>Aging</i> , 2019, 11, 7307-7327.	1.4	9
151	Adipose tissue-derived omentin-1 attenuates arterial calcification via AMPK/Akt signaling pathway. <i>Aging</i> , 2019, 11, 8760-8776.	1.4	17
152	Regulation and Potential Biological Role of Fibroblast Growth Factor 21 in Chronic Kidney Disease. <i>Frontiers in Physiology</i> , 2021, 12, 764503.	1.3	5
153	SERUM LEVEL OF FIBROBLAST GROWTH FACTOR 21 AND INSULIN RESISTANCE SYNDROME IN PATIENTS WITH CORONARY ARTERY DISEASE WITH OBESITY. <i>Bulletin of Problems Biology and Medicine</i> , 2018, 1, 108.	0.0	0
154	Metabolic Values of Fibroblasts Growth Factor 21 in Patients with Coronary Artery Disease and Obesity. <i>Ukrainian Journal of Medicine in Sport</i> , 2018, 3, 110-114.	0.0	0
157	Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 764038.	1.1	37
158	Adiponectin receptor agonist AdipoRon blocks skin inflammation and ageing by regulating mitochondrial dynamics. <i>Cell Proliferation</i> , 2021, 54, e13155.	2.4	16
159	NAFLD and Cardiovascular and Cardiac Disease: Clinical Implications. , 2020, , 169-197.		0
160	Fibroblast growth factor 21 delayed endothelial replicative senescence and protected cells from HO-induced premature senescence through SIRT1. <i>American Journal of Translational Research (discontinued)</i> , 2017, 9, 4492-4501.	0.0	28
161	FGF21 inhibitor suppresses the proliferation and migration of human umbilical vein endothelial cells through the eNOS/PI3K/AKT pathway. <i>American Journal of Translational Research (discontinued)</i> , 2017, 9, 5299-5307.	0.0	6
162	A high circulating FGF21 level as a prognostic marker in patients with acute myocardial infarction. <i>American Journal of Translational Research (discontinued)</i> , 2018, 10, 2958-2966.	0.0	9
163	Fibroblast growth factor 21 attenuates inflammation and oxidative stress in atherosclerotic rat via enhancing the Nrf1-ARE signaling pathway. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 1308-1317.	0.5	11
164	Ethyl acetate extract of sappanwood alleviates experimental atherosclerosis in rats through changes in FGF21 and SREBP-2 expression. <i>International Journal of Clinical and Experimental Pathology</i> , 2020, 13, 220-229.	0.5	2
165	The impact of different adipose depots on cardiovascular disease. <i>Journal of Cardiovascular Pharmacology</i> , 2021, Publish Ahead of Print, .	0.8	5
166	Fibroblast growth factor 21 attenuates salt-sensitive hypertension-induced nephropathy through anti-inflammation and anti-oxidation mechanism. <i>Molecular Medicine</i> , 2021, 27, 147.	1.9	8
167	Effects of an interdisciplinary weight loss program on fibroblast growth factor 21 and inflammatory biomarkers in women with overweight and obesity. <i>Archives of Endocrinology and Metabolism</i> , 2021, 65, .	0.3	2

#	ARTICLE	IF	CITATIONS
168	Dietary protein and amino acid restriction: Roles in metabolic health and aging-related diseases. <i>Free Radical Biology and Medicine</i> , 2022, 178, 226-242.	1.3	19
169	Nuclear Receptor PXR in Drug-Induced Hypercholesterolemia. <i>Cells</i> , 2022, 11, 313.	1.8	12
170	FGF21 attenuates pulmonary arterial hypertension via downregulation of miR-130, which targets PPAR δ . <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 1034-1049.	1.6	7
171	Serum Fibroblast Growth Factor 21 Level Is Associated with Aortic Stiffness in Patients on Maintenance Hemodialysis. <i>International Journal of Hypertension</i> , 2022, 2022, 1-8.	0.5	2
172	Plasma Tsukushi Concentration Is Associated with High Levels of Insulin and FGF21 and Low Level of Total Cholesterol in a General Population without Medication. <i>Metabolites</i> , 2022, 12, 237.	1.3	2
173	Fibroblast growth factor 21 reverses high-fat diet-induced impairment of vascular function via the anti-oxidative pathway in ApoE knockout mice. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 2451-2461.	1.6	9
174	Serum FGF21 Levels Predict the MACE in Patients With Myocardial Infarction After Coronary Artery Bypass Graft Surgery. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 850517.	1.1	2
175	Mitochondrial uncoupling protein 1 antagonizes atherosclerosis by blocking NLRP3 inflammasome-dependent interleukin-1 β production. <i>Science Advances</i> , 2021, 7, eabl4024.	4.7	27
176	The role of FGF21 in the pathogenesis of cardiovascular disease. <i>Chinese Medical Journal</i> , 2021, 134, 2931-2943.	0.9	25
179	The Effect of All Extremity High Intensity Interval Training on Athero-Protective Factors and Endothelial Function in Overweight and Obese Women.. <i>International Journal of Preventive Medicine</i> , 2021, 12, 141.	0.2	2
180	Adipokines, adiposity, and atherosclerosis. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 272.	2.4	38
181	The Association Between FGF21 and Diabetic Erectile Dysfunction: Evidence from Clinical and Animal Studies. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	0
182	Circulating Fibroblast Growth Factor 21 and Total Testosterone in Type 2 Diabetes Mellitus Men With Coronary Heart Disease. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2
183	Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPAR δ /FGF21 Axis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 14, 1003-1023.	2.3	8
184	Fibroblast Growth Factor-Based Pharmacotherapies for the Treatment of Obesity-Related Metabolic Complications. <i>Annual Review of Pharmacology and Toxicology</i> , 2023, 63, 359-382.	4.2	16
186	Fibroblast growth factor 21 is associated with widening QRS complex and prolonged corrected QT interval in patients with stable angina. <i>BMC Cardiovascular Disorders</i> , 2022, 22, .	0.7	0
187	FGF21-Sirtuin 3 Axis Confers the Protective Effects of Exercise Against Diabetic Cardiomyopathy by Governing Mitochondrial Integrity. <i>Circulation</i> , 2022, 146, 1537-1557.	1.6	55
188	Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine. <i>International Journal of Biological Sciences</i> , 2023, 19, 66-88.	2.6	11

#	ARTICLE	IF	CITATIONS
189	Glucose and lipopolysaccharide differentially regulate fibroblast growth factor 21 in healthy male human volunteers – A prospective crossover trial. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 5998-6005.	1.6	1
190	Adipose-targeted triiodothyronine therapy counteracts obesity-related metabolic complications and atherosclerosis with negligible side effects. <i>Nature Communications</i> , 2022, 13, .	5.8	5
192	Fibroblast growth factor 21 and prognosis of patients with cardiovascular disease: A meta-analysis. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	0
194	Liver-derived <scp>FGF21</scp> is required for the effect of time-restricted feeding on high-fat diet-induced fatty liver in mice. <i>FASEB Journal</i> , 2023, 37, .	0.2	4
210	<i>Endocrinology and metabolism</i> . , 2024, , 179-295.		0
211	<i>Growth factors reviews</i> . , 2024, , 19-112.		0
214	<i>The FGF metabolic axis</i> . , 2024, , 1-18.		0